Tweetovi

Blokirali ste korisnika/cu @pashtoonkasi

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @pashtoonkasi

  1. Prikvačeni tweet
    Poništi
  2. On 💡we really need to support more & engage in 🧬biomarker driven . Advances for many of these cancers is coming for subsets. Cancers are heterogeneous👇🏼. One size fits all approach less likely to be successful.

    , , i još njih 6
    Poništi
  3. is truly a ✅“TARGET-RICH”👇🏼 disease. 💡For sure everyone➡️genetic testing. Often tissue is ❌. One area where 🧬🩸 can fill that void. – mjesto: UIHC Holden Comprehensive Cancer Center

    , , i još njih 5
    Poništi
  4. 3. velj
    , , i još njih 7
    Poništi
  5. proslijedio/la je Tweet
    30. sij

    💡REVERCE - intriguing PFS-2/OS differences R➡️C 17.4m C➡️R 11.6m Value of Different emerging mutations 🩸🧬🧪RAS/EGFR/MET. “SEQUENCING” ➡️varied outcomes.

    Poništi
  6. proslijedio/la je Tweet
    31. sij

    👇🏼intriguing in many ways to how we treat & ♻️ therapies💡. These are tissue-RAS/RAF Wildtype patients that acquired RAS/EGFR🧬🩸🧪on . Cumulative t1/2📉4months. – mjesto: UIHC Holden Comprehensive Cancer Center

    Poništi
  7. 1. velj
    Poništi
  8. 1. velj
    Poništi
  9. proslijedio/la je Tweet
    31. sij

    MT [Sep 27, 2019] Number of actionable targets in this target-rich disease are increasing with encouraging results.

    Prikaži ovu nit
    Poništi
  10. 31. sij

    👇🏼intriguing in many ways to how we treat & ♻️ therapies💡. These are tissue-RAS/RAF Wildtype patients that acquired RAS/EGFR🧬🩸🧪on . Cumulative t1/2📉4months. – mjesto: UIHC Holden Comprehensive Cancer Center

    Poništi
  11. 31. sij

    Anyone with experiences and/or thoughts on 🧬 specifically from a metastatic cancer treatment standpoint? I found some pooled analysis of ⬆️platinum-based chemotherapy.

    Poništi
  12. 30. sij

    💡REVERCE - intriguing PFS-2/OS differences R➡️C 17.4m C➡️R 11.6m Value of Different emerging mutations 🩸🧬🧪RAS/EGFR/MET. “SEQUENCING” ➡️varied outcomes.

    Poništi
  13. 29. sij
    , , i još njih 7
    Prikaži ovu nit
    Poništi
  14. 29. sij

    Is just prognostic? ❌NO! Can you change outcomes by CLEARANCE of ? ✅YES! Remember the terms👇🏼 ➕➡️➖✅Molecular Responder ➖➡️➕ or ➕➡️➕❌Molecular Non-Responder Provides a platform.

    Prikaži ovu nit
    Poništi
  15. 29. sij

    And especially if you had detectable DNA after your induction systemic chemo or ChemoXRT & surgery: Then you’re in trouble: ominous! Doesn’t get more black and white than this.👇🏼 💯 % 🆚 0%‼️

    Prikaži ovu nit
    Poništi
  16. 29. sij

    This is from the CRITICS: ChemoRadiotherapy after Induction chemoTherapy In Cancer of the Stomach. 21.8 ✖️ higher risk of disease DFS: 18.7 m 🆚 median NR; p < 0.001; HR = 21.8;CI =3.9–123.1. OS: 28.7 🆚 median NE; p < 0.001; HR = 21.8;CI =3.9–123.1

    Prikaži ovu nit
    Poništi
  17. 29. sij

    ➕➡️➖✅Molecular Responder ➖➡️➕ or ➕➡️➕❌Molecular Non-Responder Here it shows that it’s not just prognostic but predictive like we were proposing earlier. Survival is not much different if you just detect; but if you CLEAR it after induction chemo, ⬆️survival.

    Prikaži ovu nit
    Poništi
  18. 29. sij

    Bear with me as we dissect this landmark study answering some of the 🔑❓raised at . Love the terms: ➕➡️➖✅Molecular Responder ➖➡️➕ or ➕➡️➕❌Molecular Non-Responder

    Prikaži ovu nit
    Poništi
  19. proslijedio/la je Tweet
    28. sij

    Excited about giving a talk on dysproteinemias at in Maui 🌺!

    , , i još njih 5
    Poništi
  20. proslijedio/la je Tweet
    28. sij

    With ctDNA ever more accurate that may detect resistant clones 1. (which the immune system does not recognize) 👉should we design + targeted Tx (TT) trials d/t ctDNA? Long-term dz control by only changing TT? 109

    Poništi
  21. 28. sij
    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·